Evidence map›Paper›PMID 32790106›Full record

SynthesisJournal of medical virology2021

Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes.

Jie Li, Daniel Q Huang, Biyao Zou, Hongli Yang, Wan Zi Hui, Fajuan Rui, Natasha Tang Sook Yee, Chuanli Liu, Sanjna Nilesh Nerurkar, Justin Chua Ying Kai and 7 more

Registry-linked trialOpen access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of medical virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05026879 (Adverse Events Report of Inactivated COVID-19 Vaccine From 4040 Healthcare Workers), which is not on this map. Cited by 374 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
374citing papers in PubMed, 7 pooled it
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05026879 completednot on this map

Adverse Events Report of Inactivated COVID-19 Vaccine From 4040 Healthcare Workers

TypeobservationalSponsorBozyaka Training and Research HospitalRan2021 to 2021Enrolled4,040ConditionsCOVID-19, Vaccine Adverse ReactionArmsInactivated COVID-19 vaccine (CoronaVac)
3 · Its place in the literature

Who cites it

374 citing papers in PubMed, 7 syntheses or guidelines pooled it, 762 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. When to test for COVID-19 using real-time reverse transcriptase polymerase chain reaction: a systematic review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Cellular Metabolic Signatures of Long COVID-19.Infectious disease reports · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

314 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 3 countries.

Jie LiDepartment of Infectious Disease, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China.
Daniel Q HuangDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore.
Biyao ZouDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California.
Hongli YangDepartment of Infectious Disease, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
Wan Zi HuiDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Fajuan RuiDepartment of Infectious Disease, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China.
Natasha Tang Sook YeeDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Chuanli LiuDepartment of Infectious Disease, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China.
Sanjna Nilesh NerurkarDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Justin Chua Ying KaiDepartment of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Margaret Li Peng TengDivision of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Singapore.
Xiaohe LiDivision of Infectious Disease, The Third People's Hospital of Shenzhen, Shenzhen, Guangdong, China.
Hua ZengDepartment of Internal Medicine, School of Medicine, Shenzhen University, Shenzhen, Guangdong, China.
John A BorghiLane Medical Library, School of Medicine, Stanford University, Stanford, California.
Linda HenryDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California.
Ramsey CheungDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California.
Mindie H NguyenDivision of Gastroenterology and Hepatology, Stanford University Medical Center, Stanford, California.ORCID 0000-0002-6275-4989
National University of Singapore · SGStanford Medicine · USShandong Provincial Hospital · CNShandong University · CNNational University Hospital · SGShenzhen Third People’s Hospital · CNShenzhen University · CNVA Palo Alto Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) has become a pandemic, but its reported characteristics and outcomes vary greatly amongst studies. We determined pooled estimates for clinical characteristics and outcomes in COVID-19 patients including subgroups by disease severity (based on World Health Organization Interim Guidance Report or Infectious Disease Society of America/American Thoracic Society criteria) and by country/region. We searched Pubmed, Embase, Scopus, Cochrane, Chinese Medical Journal, and preprint databases from 1 January 2020 to 6 April 2020. Studies of laboratory-confirmed COVID-19 patients with relevant data were included. Two reviewers independently performed study selection and data extraction. From 6007 articles, 212 studies from 11 countries/regions involving 281 461 individuals were analyzed. Overall, mean age was 46.7 years, 51.8% were male, 22.9% had severe disease, and mortality was 5.6%. Underlying immunosuppression, diabetes, and malignancy were most strongly associated with severe COVID-19 (coefficient =  53.9, 23.4, 23.4, respectively, all P < .0007), while older age, male gender, diabetes, and hypertension were also associated with higher mortality (coefficient = 0.05 per year, 5.1, 8.2, 6.99, respectively; P = .006-.0002). Gastrointestinal (nausea, vomiting, abdominal pain) and respiratory symptoms (shortness of breath, chest pain) were associated with severe COVID-19, while pneumonia and end-organ failure were associated with mortality. COVID-19 is associated with a severe disease course in about 23% and mortality in about 6% of infected persons. Individuals with comorbidities and clinical features associated with severity should be monitored closely, and preventive efforts should especially target those with diabetes, malignancy, and immunosuppression.

Indexed as

ComorbidityCOVID-19FemaleHospitalizationHumansMaleRisk FactorsSeverity of Illness Indexclinical characteristicsCOVID-19mortalityrisk factorssevere

Identifiers

PMID32790106
PMCPMC7436673
OpenAlexW3048804923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.